한미약품

128940KOSPI

49.0 / 100

Reference Date: 2026-10-23

Financial Score20.5 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 26.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hanmi Pharmaceuticals operates in three segments: pharmaceuticals, APIs, and overseas pharmaceuticals. It produces and sells key drugs such as the hypertension treatment 'Amozaltan' and has a global presence through its API division, Hanmi Precision Chemicals, which holds international certifications like FDA. Its overseas subsidiary, Beijing Hanmi, focuses on pediatric medications and hypertension treatments in the Chinese market.

Number of Employees

2,382people

Average Salary

86.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

27.48Industry Average 15.001.5Point

1.8x industry avg (risky)

PBR

3.31Industry Average 1.200.0Point

2.8x industry avg (risky)

ROE

14.05Industry Average 8.005.5Point

1.8x industry avg (good)

Debt Ratio

7.70Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 13.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 367,500Won52-week high 626,00052-week low 311,500

1-month return0.0Point

1m -26.65% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral결산실적공시예고(안내공시)2026-10-16
Neutral기업설명회(IR)개최(안내공시)2026-10-16
Neutral투자판단관련주요경영사항 (에페오토인젝터주(에페글레나타이드) 식품의약품안전처 품목허가 승인)2026-10-07
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-06
Neutral주식등의대량보유상황보고서(약식)2026-10-02